Back to All Combinations

MET Amp (Acquired)

Poor Prognosis
5.00% Prevalence Level 3 Resistance Mechanisms
Genes Involved
MET
Treatment Implications

Bypass resistance to anti-EGFR. Consider combo strategies.

Recommended Treatments
Treatments to Avoid
Anti-EGFR alone
Study References

Bardelli lab studies

Key Statistics
5.00%
Prevalence in CRC
No
Targetable
Clinical Notes
Check MET on anti-EGFR progression.
Information

Category: Resistance Mechanisms

Evidence Level: Level 3

Last Updated: Dec 7, 2025

Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.